Tamtam Try Tamtam free
LifeStance Health logo

LifeStance Health account plan

Behavioral health treatment services

At a glance

LifeStance Health is a US outpatient mental health platform with 8,863 clinicians and FY2025 revenue of $1,424.3 million.

LifeStance Health Group (Nasdaq: LFST), based in Scottsdale, Arizona, is one of the largest US outpatient mental health platforms, offering psychiatric treatment, psychological and neuropsychological testing and therapy in person and virtually to children, adolescents and adults. In 2025 its employed clinicians treated more than 1.0 million unique patients through approximately 9.0 million visits, and about 90% of revenue came from commercial in-network payors. FY2025 revenue was $1,424.3 million (+14%), with net income of $9.7 million and Adjusted EBITDA of $157.7 million; the company had about 10,961 employees. At September 30, 2026 it employed 8,863 clinicians, and its former private equity owners TPG and Summit held about 25.3%, so it is no longer a Nasdaq controlled company.

Strategic priorities

Clinician growth and productivity
Clinicians reached 8,863 at September 30, 2026 (+11%), and visits per average clinician rose 5% in Q3 2026; management says it uses about 70% of the time clinicians make available and aims to improve retention by five plus percent over the long run.
New EHR rollout
A new electronic health record is being tested through year end, then rolled out in phases through 2027, starting with one state; implementation is expected to cost about $20-30 million and trim 2027 revenue growth by about one to two percentage points.
Specialty services
Specialty revenue (mostly neuropsych testing, plus TMS and Spravato) of about $50 million last year is expected to grow about 40% to roughly $70 million in 2026; 37 centers offer TMS and 25 Spravato.
Geographic expansion
LifeStance is present in roughly half of the 150 largest US markets; it plans one to two tuck-in acquisitions per quarter through 2027 and assumes 20-30 de novo centers for 2027, after 20 new centers year to date in 2026.
AI and digital
AI is used in new-patient phone booking, clinical documentation, the contact center and revenue cycle management, alongside a care matching pilot to be rolled out to all state practices.
Margin expansion
The long-term target is an Adjusted EBITDA margin of 15-20%, with 20% not a ceiling, and mid-teens revenue growth; an updated long-term view is planned for the beginning of 2028.

Latest results

In Q3 2026 revenue rose 25% to $455.9 million on 2.7 million visits (+17%) and total revenue per visit of $170 (+7%). Net income was $22.4 million against $1.1 million a year earlier, Center Margin $161.4 million (35.4% of revenue) and Adjusted EBITDA $68.4 million (+70%, 15.0% margin). Nine-month revenue was $1,294.7 million (+24%) and operating cash flow $170.0 million. Full-year 2026 guidance was raised to revenue of $1.741-1.761 billion, Center Margin of $599-613 million and Adjusted EBITDA of $242-250 million; Q4 2026 guidance is revenue of $446-466 million.

Investments and deals

Electronic health record replacement
A new EHR vendor was chosen; implementation runs through 2026 and the transition through 2027, with $20-30 million of cash use, mostly capitalized or adjusted.
Tuck-in acquisitions
Four outpatient mental health practices acquired in the first nine months of 2026 for $14.1 million aggregate consideration, including an Iowa tuck-in in Q3 that took the footprint to 34 states.
Share buybacks
15 million shares repurchased for $122.4 million in the first nine months of 2026; a new $100.0 million program was approved on August 5, 2026, with $75.4 million remaining.
Second-half reinvestment
First-half upside is being reinvested in patient acquisition, tech and AI, clinical excellence teams, clinician compensation and benefits, and a refresh of some centers in Q4 2026.

Challenges and risks

Payor concentration and rates
About 90% of revenue comes from commercial in-network payors, and UnitedHealthcare (14%) and Elevance Health (15%) each exceed 10% of revenue; in 2025 total revenue per visit fell on a single payor rate decrease.
Clinician recruitment and retention
Competition for clinicians is intense, and retention is weakest among new clinicians; LifeStance holds a low single-digit share of the total clinician population.
Internal control weaknesses
Disclosure controls remained not effective at September 30, 2026 because of material weaknesses first identified for 2019, though remediation is advancing.
EHR transition disruption
Management expects the new EHR to cause a short-term blip in productivity and to reduce 2027 revenue growth toward the lower end of the mid-teens range.
Regulatory and privacy exposure
Corporate-practice-of-medicine laws underpin 392 of 572 centers run as supported practices, and a privacy class action over pixel tracking awaits settlement approval.

What leadership says

“The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations”

Dave Bourdon, Chief Executive Officer · Q3 2026 results press release, November 5, 2026

“mental health care is entering its next phase where differentiation will increasingly be driven by outcomes, not just access.”

David Bourdon, Chief Executive Officer · Q2 2026 earnings call, August 6, 2026

“We're utilizing right now about 70% of the time that clinicians give us.”

David Bourdon, Chief Executive Officer · Q2 2026 earnings call, August 6, 2026

“We expect margins to keep expanding in 2027 and beyond”

Ryan McGroarty, Chief Financial Officer · Q3 2026 earnings call, November 5, 2026

Where a supplier can help

EHR migration support
The phased EHR rollout through 2027 (data conversion, workflow standardization, reconnecting point solutions) creates demand for implementation, integration and training partners.
Patient access and scheduling
With clinicians' available time about 70% used, tools for new-patient conversion, scheduling optimization and care matching tie directly to the productivity priority.
Revenue cycle and payor work
Payor concentration and annual rate negotiations, supported by outcomes data, point to revenue cycle automation, analytics and outcome measurement suppliers.
Clinician recruiting and retention
Clinician growth is the main revenue driver, so recruiting, credentialing, benefits and retention solutions address a core challenge.
Center build-out and specialty equipment
20-30 new centers a year, center refreshes and the expansion of TMS and Spravato sites need real estate, fit-out and specialty treatment suppliers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like LifeStance Health?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about LifeStance Health

What does LifeStance Health do?

LifeStance provides outpatient mental healthcare in person and virtually, including psychiatric treatment, psychological and neuropsychological testing and therapy, through employed clinicians. It operates more than 575 centers across 35 states, per its Q3 2026 release.

What is LifeStance Health's revenue?

FY2025 revenue was $1,424.3 million, up 14%. For 2026 the company guides to revenue of $1.741-1.761 billion, after Q3 2026 revenue of $455.9 million (+25%).

How many employees does LifeStance have?

LifeStance had about 10,961 employees at the end of 2025, and employed 8,863 licensed clinicians at September 30, 2026.

What is LifeStance's growth strategy?

It grows through in-house clinician recruiting, new centers, tuck-in acquisitions of independent practices and payor and referral partnerships, while expanding specialty services such as TMS and Spravato.

Who leads LifeStance Health?

David Bourdon is Chief Executive Officer and Ryan McGroarty is Chief Financial Officer; Ken Burdick moved from Executive Chair to Non-Executive Chair.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)